These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 19549707)

  • 21. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
    Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
    Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?
    Mutlu H; Salim DK; Gündüz Ş; Eryılmaz MK; Musri FY; Coşkun HŞ
    J Cancer Res Ther; 2017; 13(3):510-513. PubMed ID: 28862218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.
    Strojan P; Grašič Kuhar C; Žumer B; Kadivec M; Karner K; Fajdiga I; Jančar B; Gale N; Poljak M; Kocjan BJ; Zakotnik B
    Head Neck; 2014 Nov; 36(11):1555-61. PubMed ID: 24123552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
    Lee J; Im YH; Cho EY; Hong YS; Lee HR; Kim HS; Kim MJ; Kim K; Kang WK; Park K; Shim YM
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):77-84. PubMed ID: 17762932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma.
    Bazarbashi S; Rahal M; Raja MA; El Weshi A; Pai C; Ezzat A; Ajarim D; Memon M; Al Fadda M
    Chemotherapy; 2002 Sep; 48(4):211-6. PubMed ID: 12218269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.
    Rosell R; Robinet G; Szczesna A; Ramlau R; Constenla M; Mennecier BC; Pfeifer W; O'Byrne KJ; Welte T; Kolb R; Pirker R; Chemaissani A; Perol M; Ranson MR; Ellis PA; Pilz K; Reck M
    Ann Oncol; 2008 Feb; 19(2):362-9. PubMed ID: 17947225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma.
    Tian J; Shang M; Shi SB; Han Y; Xu J
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):829-34. PubMed ID: 26330330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
    Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
    Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus.
    Wadler S; Haynes H; Beitler JJ; Hu X; Fell S; Camacho M; Levine B; Wiernik PH
    Cancer; 1996 Jul; 78(1):30-4. PubMed ID: 8646722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Bourhis J; Rivera F; Mesia R; Awada A; Geoffrois L; Borel C; Humblet Y; Lopez-Pousa A; Hitt R; Vega Villegas ME; Duck L; Rosine D; Amellal N; Schueler A; Harstrick A
    J Clin Oncol; 2006 Jun; 24(18):2866-72. PubMed ID: 16717293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus.
    Polee MB; Kok TC; Siersema PD; Tilanus HW; Splinter TA; Stoter G; Van der Gaast A
    Anticancer Drugs; 2001 Jul; 12(6):513-7. PubMed ID: 11459997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
    Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
    Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma.
    Olivatto LO; Vieira FM; Pereira BV; Victorino AP; Bezerra M; Araujo CM; Erlich F; Faroni L; Castro L; Lusis EC; Marins A; Ferreira CG
    Cancer; 2013 Aug; 119(16):2973-80. PubMed ID: 23674135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.
    Perri F; Muto P; Argenone A; Ionna F; Longo F; Fulciniti F; Sandomenico F; Daponte A; Caponigro F
    Oncology; 2013; 84(4):251-4. PubMed ID: 23428719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.
    Cohen MH; Chen H; Shord S; Fuchs C; He K; Zhao H; Sickafuse S; Keegan P; Pazdur R
    Oncologist; 2013; 18(4):460-6. PubMed ID: 23576486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study.
    Merlano M; Russi E; Benasso M; Corvò R; Colantonio I; Vigna-Taglianti R; Vigo V; Bacigalupo A; Numico G; Crosetto N; Gasco M; Lo Nigro C; Vitiello R; Violante S; Garrone O
    Ann Oncol; 2011 Mar; 22(3):712-717. PubMed ID: 20810547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
    Luber B; Deplazes J; Keller G; Walch A; Rauser S; Eichmann M; Langer R; Höfler H; Hegewisch-Becker S; Folprecht G; Wöll E; Decker T; Endlicher E; Lorenzen S; Fend F; Peschel C; Lordick F
    BMC Cancer; 2011 Dec; 11():509. PubMed ID: 22152101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Al-Batran SE; Hartmann JT; Probst S; Schmalenberg H; Hollerbach S; Hofheinz R; Rethwisch V; Seipelt G; Homann N; Wilhelm G; Schuch G; Stoehlmacher J; Derigs HG; Hegewisch-Becker S; Grossmann J; Pauligk C; Atmaca A; Bokemeyer C; Knuth A; Jäger E;
    J Clin Oncol; 2008 Mar; 26(9):1435-42. PubMed ID: 18349393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma.
    Honda M; Miura A; Izumi Y; Kato T; Ryotokuji T; Monma K; Fujiwara J; Egashira H; Nemoto T
    Dis Esophagus; 2010 Nov; 23(8):641-5. PubMed ID: 20545978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.